NO327733B1 - Anvendelse av Gingko biloba-ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sklerose - Google Patents
Anvendelse av Gingko biloba-ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sklerose Download PDFInfo
- Publication number
- NO327733B1 NO327733B1 NO20010627A NO20010627A NO327733B1 NO 327733 B1 NO327733 B1 NO 327733B1 NO 20010627 A NO20010627 A NO 20010627A NO 20010627 A NO20010627 A NO 20010627A NO 327733 B1 NO327733 B1 NO 327733B1
- Authority
- NO
- Norway
- Prior art keywords
- extract
- ginkgo biloba
- extracts
- treatment
- ginkgolides
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 38
- 244000194101 Ginkgo biloba Species 0.000 title claims abstract description 25
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 title claims description 5
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 24
- 229930184727 ginkgolide Natural products 0.000 claims abstract description 22
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- -1 flavone glycosides Chemical class 0.000 claims description 9
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 8
- 229930003944 flavone Natural products 0.000 claims description 8
- 235000011949 flavones Nutrition 0.000 claims description 8
- 229930182470 glycoside Natural products 0.000 claims description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 8
- 229920002770 condensed tannin Polymers 0.000 claims description 2
- 229920001991 Proanthocyanidin Polymers 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000011201 Ginkgo Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 2
- LMEHVEUFNRJAAV-HOSIAMDISA-N ginkgolide J Natural products O=C1[C@H](C)[C@@]2(O)[C@H](O1)C[C@@]13[C@H]4[C@@H](O)[C@@H](C(C)(C)C)[C@@]51[C@@H](O)C(=O)O[C@@H]5O[C@@]23C(=O)O4 LMEHVEUFNRJAAV-HOSIAMDISA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960004181 riluzole Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- AMOGMTLMADGEOQ-FNZROXQESA-N Ginkgolide C Chemical compound O([C@H]1O2)C(=O)[C@H](O)C31[C@]14[C@@H](O)[C@@H]5OC(=O)[C@@H](C)[C@]5(O)[C@@]12C(=O)O[C@@H]4[C@@H](O)[C@H]3C(C)(C)C AMOGMTLMADGEOQ-FNZROXQESA-N 0.000 description 1
- CBAUUWCEZZNYTD-OOWJTCQTSA-N Ginkgolide M Natural products O=C1[C@@H](C)[C@@H]2[C@@H]([C@@H](O)[C@@]34[C@H]5[C@@H](O)[C@@H](CC(C)C)[C@@]63[C@@H](O)C(=O)O[C@@H]6O[C@@]24C(=O)O5)O1 CBAUUWCEZZNYTD-OOWJTCQTSA-N 0.000 description 1
- KDKROYXEHCYLJQ-DYXVGVPESA-N Ginkgolide M Chemical compound C[C@H]1[C@H]2[C@H]([C@@H](C34[C@]25C(=O)O[C@@H]3[C@@H]([C@H](C46[C@H](C(=O)O[C@H]6O5)O)C(C)(C)C)O)O)OC1=O KDKROYXEHCYLJQ-DYXVGVPESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007357 Nauclea orientalis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 1
- AMOGMTLMADGEOQ-DPFZUGDXSA-N ginkgolide C Natural products O=C1[C@@H](C)[C@]2(O)[C@H]([C@H](O)[C@@]34[C@H]5[C@H](O)[C@@H](C(C)(C)C)[C@]63[C@H](O)C(=O)O[C@H]6O[C@@]24C(=O)O5)O1 AMOGMTLMADGEOQ-DPFZUGDXSA-N 0.000 description 1
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 1
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 description 1
- LMEHVEUFNRJAAV-UKWFQYJJSA-N ginkgolide-j Chemical compound O([C@H]1O2)C(=O)[C@H](O)[C@@]31[C@]14C[C@@H]5OC(=O)[C@@H](C)[C@]5(O)[C@@]12C(=O)O[C@@H]4[C@H](O)[C@H]3C(C)(C)C LMEHVEUFNRJAAV-UKWFQYJJSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102220020162 rs397508045 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9810187A FR2782008B1 (fr) | 1998-08-07 | 1998-08-07 | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique |
PCT/FR1999/001948 WO2000007592A1 (fr) | 1998-08-07 | 1999-08-06 | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20010627D0 NO20010627D0 (no) | 2001-02-06 |
NO20010627L NO20010627L (no) | 2001-02-06 |
NO327733B1 true NO327733B1 (no) | 2009-09-14 |
Family
ID=9529516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20010627A NO327733B1 (no) | 1998-08-07 | 2001-02-06 | Anvendelse av Gingko biloba-ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sklerose |
Country Status (12)
Country | Link |
---|---|
US (1) | US6524629B1 (pt) |
EP (1) | EP1102586B1 (pt) |
JP (1) | JP4510289B2 (pt) |
AT (1) | ATE281162T1 (pt) |
AU (1) | AU5170499A (pt) |
CA (1) | CA2340021C (pt) |
DE (1) | DE69921662T2 (pt) |
ES (1) | ES2230873T3 (pt) |
FR (1) | FR2782008B1 (pt) |
NO (1) | NO327733B1 (pt) |
PT (1) | PT1102586E (pt) |
WO (1) | WO2000007592A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2785808B1 (fr) * | 1998-11-13 | 2002-12-06 | Aventis Laboratoire | Association riluzole et alpha-tocopherol |
FR2827518B1 (fr) * | 2001-07-17 | 2005-07-08 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie |
JP4528490B2 (ja) * | 2002-06-25 | 2010-08-18 | 和光化学株式会社 | ギンコライド−aを含有する抗不安剤 |
US8024893B2 (en) | 2003-02-19 | 2011-09-27 | Pilkington North America, Inc. | Powered slider drive interface and drive assembly |
MXPA05011772A (es) * | 2003-05-02 | 2006-07-06 | Univ Georgetown | Extractos de ginkgo biloba como un tratamiento para neurotoxicidad terapeuticamente inducida. |
WO2006004386A1 (es) * | 2004-07-02 | 2006-01-12 | Rojas Castaneda Patricia | Uso de un extracto del ginkgo biloba para preparar una medicina para tratar la enfermedad de parkinson |
EP1949085A4 (en) * | 2005-09-30 | 2010-02-17 | Kinemed Inc | SYNTHESIS OF MICROTUBLES AS A BIOMARKER |
AU2007204991A1 (en) * | 2006-01-05 | 2007-07-19 | Kinemed, Inc. | Compositions and methods of treatment using modulators of motonueron diseases |
FR2904222A1 (fr) | 2006-07-27 | 2008-02-01 | Sod Conseils Rech Applic | Utilisation d4extraits de ginkgo biloba pour le traitement de maladies mitochondriales |
CA2725138A1 (en) * | 2008-05-21 | 2009-11-26 | Kinemed, Inc. | Compositions and methods of treatment using modulators of motoneuron diseases |
GB0922064D0 (en) | 2009-12-17 | 2010-02-03 | Pilkington Group Ltd | Soda lime silica glass composition |
US20150045330A1 (en) * | 2012-01-17 | 2015-02-12 | Kyoto University | Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor |
WO2016114655A1 (en) * | 2015-01-12 | 2016-07-21 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
WO2017065602A1 (en) * | 2015-10-13 | 2017-04-20 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
CN108096243B (zh) * | 2017-11-24 | 2020-05-29 | 江苏康缘药业股份有限公司 | 银杏内酯组合物的医药用途 |
CN110893183A (zh) * | 2018-09-13 | 2020-03-20 | 成都百裕制药股份有限公司 | 银杏萜内酯在制备预防、缓解或治疗肌萎缩侧索硬化药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3338995A1 (de) * | 1983-10-27 | 1985-05-09 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | Bilobalid enthaltende arzneimittel |
DE3940094A1 (de) * | 1989-12-04 | 1991-06-06 | Montana Ltd | Wirkstoffkonzentrate und neue wirkstoff-kombinationen aus blaettern von ginkgo biloba, ein verfahren zu ihrer herstellung und die wirkstoff-konzentrate bzw. die wirkstoff-kombinationen enthaltenden arzneimittel |
DE4328374A1 (de) * | 1993-08-24 | 1995-03-02 | Deinlein Kalb Hans | Neue Verwendung eines Extraktes aus den Blättern von Ginkgo biloba |
ES2159362T3 (es) * | 1995-10-26 | 2001-10-01 | Sanofi Synthelabo | Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica. |
-
1998
- 1998-08-07 FR FR9810187A patent/FR2782008B1/fr not_active Expired - Fee Related
-
1999
- 1999-08-06 JP JP2000563277A patent/JP4510289B2/ja not_active Expired - Fee Related
- 1999-08-06 CA CA002340021A patent/CA2340021C/fr not_active Expired - Fee Related
- 1999-08-06 WO PCT/FR1999/001948 patent/WO2000007592A1/fr active IP Right Grant
- 1999-08-06 ES ES99936702T patent/ES2230873T3/es not_active Expired - Lifetime
- 1999-08-06 EP EP99936702A patent/EP1102586B1/fr not_active Expired - Lifetime
- 1999-08-06 AT AT99936702T patent/ATE281162T1/de active
- 1999-08-06 DE DE69921662T patent/DE69921662T2/de not_active Expired - Lifetime
- 1999-08-06 PT PT99936702T patent/PT1102586E/pt unknown
- 1999-08-06 US US09/744,464 patent/US6524629B1/en not_active Expired - Lifetime
- 1999-08-06 AU AU51704/99A patent/AU5170499A/en not_active Abandoned
-
2001
- 2001-02-06 NO NO20010627A patent/NO327733B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2340021C (fr) | 2009-09-15 |
FR2782008A1 (fr) | 2000-02-11 |
EP1102586A1 (fr) | 2001-05-30 |
ATE281162T1 (de) | 2004-11-15 |
CA2340021A1 (fr) | 2000-02-17 |
NO20010627D0 (no) | 2001-02-06 |
WO2000007592A1 (fr) | 2000-02-17 |
FR2782008B1 (fr) | 2003-04-25 |
ES2230873T3 (es) | 2005-05-01 |
AU5170499A (en) | 2000-02-28 |
JP4510289B2 (ja) | 2010-07-21 |
NO20010627L (no) | 2001-02-06 |
DE69921662T2 (de) | 2005-10-20 |
US6524629B1 (en) | 2003-02-25 |
EP1102586B1 (fr) | 2004-11-03 |
PT1102586E (pt) | 2005-02-28 |
DE69921662D1 (de) | 2004-12-09 |
JP2002522387A (ja) | 2002-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO327733B1 (no) | Anvendelse av Gingko biloba-ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sklerose | |
AU2003227516B2 (en) | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
US5336675A (en) | Method of treating mania in humans | |
US4888347A (en) | Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration | |
US4427694A (en) | Sesamin as a psychotropic agent | |
EP2332533A1 (en) | Cannabinoid-containing plant extracts as neuroprotective agents | |
Rami et al. | Neuronal protective effects of calcium antagonists in cerebral ischemia | |
JP2010514790A (ja) | 治療処置のための方法および組成物 | |
WO2006001665A1 (en) | Composition for preventing or treating acute or chronic degenerative brain diseases including flavonoid derivatives | |
JPH02256663A (ja) | 不安および不安抑うつ障害の処置に有用な医薬組成物の調製へのトリフルオロメチルフェニルテトラヒドロピリジンの使用 | |
RU2207140C2 (ru) | Применение экстрактов гинкго двудольного для приготовления лекарственного средства | |
US6476203B1 (en) | Safe pharmaceutical composition for treating and preventing infertility and increasing immune function | |
RU2298411C2 (ru) | Применение экстрактов ginkgo biloba для получения лекарственного средства, предназначенного для лечения саркопении | |
NZ189159A (en) | Oral antihypertensive compositions containing proline derivatives | |
IE930485A1 (en) | Antidepressant agents with a rapid onset of action | |
Ahtee et al. | The fall of homovanillic acid and 5-hydroxyindoleacetic acid concentrations in brains of mice withdrawn from repeated morphine treatment and their restoration by acute morphine administration | |
Sramek et al. | Placebo‐controlled study of ABT‐200 versus fluoxetine in the treatment of major depressive disorder | |
EP2305273B1 (en) | Use of icariside II for the prevention or treatment of erectile dysfunction | |
KR20040042305A (ko) | 조구등을 주성분으로 함유하는 치매치료의 의약조성물 | |
JP3615704B2 (ja) | 喫煙制御の改良組成物および方法 | |
CA2062094C (en) | Method of treating mania | |
US8097287B2 (en) | Use of a Ginkgo biloba extract for the treatment of mitochondrial disease of genetic origin | |
MXPA04012754A (es) | Interaccion sinergica de abacavir y alovudina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |